anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Periprosthetic joint infection (PJI) is a devastating complication after total hip and total knee arthroplasty (THA/TKA). While some guidelines no longer recommend routine use of prophylactic antibiotics for dental procedures, many surgeons continue to prescribe antibiotics for their THA/TKA patients. In a setting of increasing antibiotic resistance, it is important to reduce unnecessary antibiotic use. This study aims to evaluate antibiotics prior to dental procedures and the association between dental procedures and PJI.
METHODS: We conducted a retrospective cohort study of patients who underwent THA/TKA between January 1, 2019 and December 31, 2020. The primary outcome was late-presenting PJI, occurring > 90 days after surgery. Patients were designated in the antibiotic group (2,000 mg of amoxicillin) or non-antibiotic group based on their surgeon's prophylaxis protocol. Dental-associated PJIs were considered if the patient had evidence of poor dentition or a recent dental procedure prior to the onset of PJI symptoms.
RESULTS: There were 2,871 (26.4%) patients in the no antibiotics group and 8,023 (73.6%) patients in the antibiotics group. We found 27 (0.3%) late-presenting PJIs and 4 dental-associated PJIs. In the univariate and multivariable analyses, body mass index ≥-30 and revision surgery were the only variables that increased the odds of late-presenting PJI. All 4 dental-associated PJIs occurred in patients prescribed antibiotics.
CONCLUSIONS: We found a low rate of late-presenting PJI. Routine antibiotics prior to dental procedures were not shown to affect the risk of late-presenting PJI. These findings suggest that routine antibiotic prophylaxis before dental procedures is not necessary after THA/TKA.
Subjects will receive an RF treatment session on the periorbital area and cheeks with a frequency of 1 and 4 MHz. Each subject will be treated on one side of the face using a 10 mm capacitive electrode, and on the other side using a 20 mm capacitive electrode. The target temperature will be set at 42 C.
A blood substitute which contains a purge solution and a maintenance solution, the latter of which is useful for organ preservation is disclosed. The purge solution contains an aqueous solution of electrolytes at physiological concentrations, a macromolecular oncotic agent, a biological pH buffer, a simple sugar, and a substrate for the regeneration of ATP. The maintenance solution contains a second aqueous solution of electrolytes containing potassium ions (35-45 mM), sodium ions (80-120 mM), magnesium ions (2-10 mM), chloride ions (15-20 mM), and calcium ions (0.01-0.1 mM), an impermeant anion, mannitol, a macromolecular oncotic agent, at least one simple sugar, a substrate for the regeneration of ATP, and a biological pH buffer. Glutathione is an optional additive. The blood substitute solutions are also useful for preserving organs for later transplantation in subjects. Skin may be preserved in the maintenance solutions for extended periods under refrigeration.
Sesquiterpenes are a class of metabolites derived from plant species with immunomodulatory activity. In this study, we evaluated the effects of treatment with costic acid on inflammation, angiogenesis, and fibrosis induced by subcutaneous sponge implants in mice. One sponge disc per animal was aseptically implanted in the dorsal region of the mice and treated daily with costic acid (at concentrations of 0.1, 1, and 10 μg diluted in 10 μL of 0.5% DMSO) or 0.5% DMSO (control group). After 9 days of treatment, the animals were euthanized, and the implants collected for further analysis. Treatment with costic acid resulted in the reduction of the inflammatory parameters evaluated compared to the control group, with a decrease in the levels of inflammatory cytokines and chemokines (TNF, CXCL-1, and CCL2) and in the activity of MPO and NAG enzymes. Costic acid administration altered the process of mast cell degranulation. We also observed a reduction in angiogenic parameters, such as a decrease in the number of blood vessels, the hemoglobin content, and the levels of VEGF and FGF cytokines. Finally, when assessing implant-induced fibrogenesis, we observed a reduction in the levels of the pro-fibrogenic cytokine TGF-β1, and lower collagen deposition. The results of this study demonstrate, for the first time, the anti-inflammatory, anti-angiogenic, and anti-fibrotic effects of costic acid in an in vivo model of chronic inflammation and reinforce the therapeutic potential of costic acid.
In controlled clinical trials for the management of acne vulgaris, the occurrence of adverse reactions associated with the use of Klaron Lotion was infrequent and restricted to local events. The total incidence of adverse reactions reported in these studies was less than 2%. Only one of 105 patients treated with Klaron Lotion had adverse reactions of erythema, itching, and edema. It has been reported that sodium sulfacetamide may cause local irritation, stinging, and burning. While the irritation may be transient, occasionally the use of medication has to be discontinued.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Safety and effectiveness in the pediatric population other than pediatric patients with nocturnal enuresis have not been established (see BOX WARNING and WARNINGS: Clinical Worsening and Suicide Risk). Anyone considering the use of imipramine hydrochloride in a child or adolescent must balance the potential risks with the clinical need.

The safety and effectiveness of the drug as temporary adjunctive therapy for nocturnal enuresis in pediatric patients less than 6 years of age has not been established.

The safety of the drug for long-term, chronic use as adjunctive therapy for nocturnal enuresis in pediatric patients 6 years of age or older has not been established; consideration should be given to instituting a drug-free period following an adequate therapeutic trial with a favorable response.

A dose of 2.5 mg/kg/day should not be exceeded in childhood. ECG changes of unknown significance have been reported in pediatric patients with doses twice this amount.
Subjects were randomized to receive comedone extraction. Comedone extraction were done three times, and evaluated every 2 weeks.
PCT No. PCT/US90/03367 Sec. 371 Date Dec. 12, 1991 Sec. 102(e) Date Dec. 12, 1991 PCT Filed Jun. 13, 1990.A method of inhibiting the production of interleukin-1 by monocytes and/or macrophages in a human in need thereof which comprises administering to such a human an effective, interleukin-1 production inhibiting amount of a diaryl-substituted imidazole fused to a second heterocyclic ring containing a nitrogen bridgehead atom wherein said second ring may also contain sulfur, oxygen or an additional nitrogen atom, and may contain additional unsaturation. This invention relates to a method of inhibiting the production of Tumor Necrosis Factor (TNF) by monocytes or macrophages in a human in need thereof which comprises administering to such mammal an effective, TNF production inhibiting amount of a compound of Formula (I) as described herein. The compounds of Formula (II) are generally described as diaryl-substituted imidazole fused to a second heterocyclic ring containing a nitrogen bridgehead wherein said ring may also contain sulfur, oxygen, or an additional nitrogen atom, and may contain additional unsaturation.
[US5317019A]
Experimental: Ainara Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
PURPOSE: To obtain a pharmaceutical preparation, comprising a sulfonylurea compound and useful for treating and/or preventing edema. CONSTITUTION: This pharmaceutical preparation is obtained by including a sulfonylurea compound which is an oral hypoglycemic agent widely used in treatment of non-insulin-dependent type diabetes, e.g. tolbutamide (N-butyl-N'- toluene-p-sulfonylurea) as an active ingredient therein. The daily dose of the compound is within the range of 5mg to 5g, but is preferably within the range of 2.5mg to 2 g in the case of administration for a long period. There is a fear of causing hypoglycemia by administering the pharmaceutical preparation. In this case, glucose is further contained or the compound is administered together with the glucose.
Patients receive ascorbic acid IV on days 1, 3 and 5 and decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 12 cycles may continue decitabine with or without ascorbic acid as long as clinically appropriate. Patients may also take vitamin C PO on days 6-28. Patients undergo PICC or portacath placement prior to starting treatment, blood sample collection, bone marrow aspiration and biopsy throughout study.
PURPOSE: Uterine serous carcinoma (USC) is a highly aggressive and frequently recurring subtype of endometrial cancer with limited treatment options for advanced or recurrent stages. Sulindac, a classic non-steroidal anti-inflammatory drug, has demonstrated anti-tumor activity in several pre-clinical tumor models. This study aims to evaluate the effect of sulindac on cell proliferation and invasion in USC cells.
METHODS: Human USC cell lines ARK-1 and SPEC2 were treated with different concentrations of sulindac. Cell proliferation was assessed using MTT and colony formation assays. ELISA assays measured cellular stress, cleaved caspase 3 activity, antioxidant ability, and adhesion. Cell cycle arrest was evaluated by Cellometer. The invasive capability was detected by wound healing assay. Western blotting was used to analyze the changes in protein expression induced by sulindac.
RESULTS: Exposure to sulindac decreased cellular viability in a dose-dependent manner in ARK-1 and SPEC2 cells. Sulindac effectively inhibited cell cycle progression, increased cellular stress, caused apoptosis, and reduced cell adhesion and invasion in USC cells. Additionally, sulindac decreased the expression of COX-2 and blocked phosphorylation of NF-κB induced by TNF-α.
CONCLUSION: Sulindac is a potential therapeutic agent for USC that deserves further exploration in pre-clinical studies and potentially future clinical trials.
A germicidal detergent composition comprises a soap or non-soap surface active agent and as active ingredient 1-hydroxy-2-pyridine thione or a salt thereof or 2,21-dithiopyridine-1,11-dioxide. Specified anionic surface active agents are the sodium, potassium, ammonium and alkyl ammonium salts of C10-C20 fatty acids; alkyl glyceryl ether sulphonates; alky sulphates; alkyl monoglyceride sulphates or sulphonates; alkyl polyethanoxy ether sulphates; acyl sarcosinates; sulphonated C16 petroleum hydrocarbons; sodium alkyl naphthalene sulphonate; diamyl sodium sulphosuccinate; mixed polyphosphates; acyl esters of isethionates; acyl N-methyl taurides; alkyl benzene sulphonates and alkyl phenol polyethanoxy sulphonates. The alkyl and acyl groups contain 10 to 20 carbon atoms and the compounds are used as their sodium, potassium ammonium and alkylol ammonium salts. Specified cationic detergents are dilauryl dimethyl ammonium chloride; diisobutyl phenoxy ethoxyethyl dimethyl benzyl ammonium chlorides; cetyl trimethyl ammonium bromide; N-cetyl pyridinium bromide and benzethonium chloride.  Specified amphoteric detergents are long chain fatty acid amides containing several amine groups; alkyl beta imino dipropionates of alkyl beta amino propionates wherein the alkyl group has 10 to 20 carbon atoms and imidazoline derivatives of the Miranol class.  Specified nonionic detergents are ethylene oxide condensates of solution fatty acids, lauryl alcohol and polypropylene and polyoxyethylene ether. The compositions may be used as shampoos, bars or powders.  Other specified ingredients are paraffin, sodium chloride, sodium sulphate, acetylated lanolin, perfumes, colours, thickeners, e.g. sodium carboxy methyl cellulose, opacifiers, suds builders, preservatives, antistatic agents, binders, emollients and fillers.ALSO:A germicidal composition comprises a soap or non-soap surface-active agent and as active ingredient 1-hydroxy-2-pyridine thione or a salt thereof or 2,21-dithiopyridine-1,11-dioxide.  Specified salts are the sodium, zinc, iron, lithium, potassium, magnesium, barium, calcium, strontium, cadmium, aluminium and lead, or cetyl ammonium salts of 1-hydroxy-2-pyridine thione.  A shampoo composition containing phenyl mercuric acetate and the active ingredient specified above is described.  Numerous anionic, non-ionic, cationic and amphoteric surface-active agents and mixtures thereof are specified.  The composition may be in the form of a liquid, bar or powder.  The compositions may also contain paraffin, colours, perfumes, emollients, binders and inert fillers.
The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. The researcher will heat the thermoregulated electric pad and set it to 42°C. After making sure that there are no contraindications in the application of the electric pad device, a dry heat of 42°C will be applied to the determined area with the electric pad for 5 minutes.
The aim of this study was to conduct a systematic review of research investigating the potential role of microsatellite instability (MSI) and loss of heterozygosity (LOH) in oral squamous cell carcinoma (OSCC), with a focus on molecular mechanisms, detection methods, and therapeutic approaches. Search for articles involved the PubMed and Scopus. Previous retrospective and prospective studies identified variations between oral cancers that exhibit microsatellite stability and LOH. In this search, 294 articles were initially retrieved. Of these, 70 were excluded due to duplication, 106 were identified as ineligible by automated tools, and 24 were excluded as they were published in languages other than English. An additional 94 articles were excluded, 32 of which focused on head and neck cancers broadly, and 8 could not be accessed due to withdrawal. Ultimately, a systematic review was conducted based on 54 selected articles. Among the chromosomes analyzed for MSI and LOH, the highest frequency of LOH was observed on chromosome 9p. The MSI subtype is particularly susceptible to immunotherapeutic methods, such as the use of anti-PD-L1 and anti-CTLA4 antibodies, owing to its strong immunogenicity and ubiquitous expression of immune checkpoint ligands. Given the distinct characteristics and clinical behavior of oral cancer with MSI compared to microsatellite stable disease, it is advisable to incorporate MSI testing into the diagnostic process for all stages of tumor development. This ensured that each patient had received precise and effective treatment.
An electroencephalographic (EEG) signature of auditory hallucinations (AHs) is important for facilitating the diagnosis and treatment of AHs in schizophrenia. We recorded EEG from 25 schizophrenia patients with recurrent AHs. During the period of AHs, EEG recordings exhibited significantly elevated beta2-band power in the temporal region, as compared to those recorded in the absence of AHs or during stimulation with verbal sounds. We further generated methamphetamine-treated rhesus monkeys exhibiting psychosis-like behaviors, including repetitive sudden searching actions in the absence of external intrusion, suggesting the occurrence of AHs. Epidural EEG beta2-band power in the temporal region of these monkeys was enhanced immediately after methamphetamine treatment and positively correlated with the frequency of sudden searching actions. Thus, the enhancement of temporal beta2-band oscillations represents a signature for AHs in both patients and a monkey model of psychosis, and this monkey model can be used for developing closed-loop neuromodulation approaches for the treatment of refractory AHs in schizophrenia.
Emerging evidence suggests that autobiographical memory (ABM) is altered in Huntington's disease (HD). While these impairments are typically attributed to frontostriatal dysfunction, the neural substrates of ABM impairment in HD remain unexplored. To this end, we assessed ABM in 30 participants with genetically confirmed HD (18 premanifest, 12 manifest) and 24 age-matched healthy controls. Participants completed the Autobiographical Interview to assess free and probed ABM recall and underwent structural brain imaging. Whole-brain voxel-based morphometry (VBM) was used to explore voxel-wise associations between ABM performance and grey matter intensity (False Discovery Rate corrected at q = 0.05). Relative to controls, HD participants displayed significantly less detailed ABM retrieval across free and probed recall conditions, irrespective of disease stage. Recall performance did not differ significantly between manifest and premanifest HD groups. VBM analyses indicated that poorer ABM performance was associated with atrophy of a distributed cortico-subcortical network. Key regions implicated irrespective of ABM condition included the bilateral occipital cortex, left precuneus, right parahippocampal gyrus and right caudate nucleus. In addition, probed ABM recall was associated with the superior and inferior frontal gyri, frontal pole, right hippocampus, nucleus accumbens, paracingulate gyrus and cerebellum. Overall, our findings indicate that ABM impairments in HD reflect the progressive degeneration of a distributed cortico-subcortical brain network comprising medial temporal, frontal, striatal and posterior parietal cortices. Our findings advance our understanding of the neurocognitive profile of HD, providing an important foundation for future interventions to support memory function in this population.
A physiological monitoring device and a product-service shopping guide method are provided. The physiological monitoring device includes an image capturing device, a contact sensing device and a processor. The image capturing device obtains the user's first physiological measurement information. The contact sensing device obtains the user's second physiological measurement information. The processor obtains the user's recommended combination of product-service according to the first physiological measurement information and the second physiological measurement information. The first physiological measurement information is used for looking up the first physiological state table to obtain the first physiological parameter, and the second physiological measurement information is used for looking up the second physiological state table to obtain the second physiological parameter. The first physiological parameter and the second physiological parameter are used for analyzing and evaluating the user's comprehensive body information, and the comprehensive physical information is used for obtaining and presenting a recommended combination of product-service for the user.
PURPOSE:To prepare the titled plaster exhibiting the magnetic effect and the anti-inflammatory and analgesic effect at the same time to improve the remedying effect by integrating a magnet with an anti-inflammatory and analgesic plaster, and having the shape of a web or sheet to facilitate the covering of the effective spot or the diseased part. CONSTITUTION:A web or sheet magnetic plastic for medical use having excellent remedying effect to shoulder discomfort, lumbago, muscular pain, etc. is prepared either by mixing a powdery, granular or solid ferrite magnet (e.g. barium or strontium ferrite magnet, metallic magnet, rare earth magnet, Alnico magnet, etc.) in a rubber or a plastic to obtain a plate A of a flexible magnet, and applying or bonding the anti-inflammatory and analgesic plaster agent B for medical use to the surface of the plate A, or by kneading a powdery, granular or solid barium ferrite magnet, strontium ferrite magnet, rare earth magnet, etc. D with an anti-inflammatory and analgesic agent E to obtain a composite F, and applying the composite F to the cloth C of fibers, etc.
PURPOSE:To obtain the titled compound useful as pharmaceuticals such as analgesic, etc., in high purity, by recrystallizing 2-(10,11-dihydro-10-oxobenzo[b, f]thiepin-2-yl)propionic acid with acetone-water. CONSTITUTION:1pt.wt. of 2-(10,11-dihydro-10-oxobenzo[b,f]thiepin-2-yl)propionic acid of formula is mixed with 3-10pts. (W/V), preferably 4-8pts. of acetone and 50-60% water based on the acetone. Preferably after seeding nuclei of the compound of formula, the mixture is vigorously agitated and added dropwise with water of an amount of 1.4-2.0 times the volume of the acetone. The water is preferably dripped little by little at the initial stage. After the completion of dripping, the agitation of the mixture is continued and the precipitated crystal is separated by filtration, washed with acetone-water mixture and dried at <=60 deg.C to obtain the objective compound.
OBJECTIVE: Evaluate a prototype dynamic laryngoplasty system (DLPS) in horses; a feasibility study.
ANIMALS: 7 healthy Standardbred adult horses.
METHODS: This was an in vivo experimental study. Horses had a standing surgical procedure to induce complete laryngeal hemiplegia, which was subsequently treated using the dynamic laryngoplasty system (DLPS). Activation of the DLPS was achieved using an injection port exiting through the skin (n = 2) or a subcutaneous injection port (n = 5). For each horse, endoscopic examinations of the upper respiratory tract were performed preoperatively, intraoperatively, and 7 days postoperatively. Left-to-right quotient ratios calculated during inactivated and activated states were obtained from still images of the rima glottidis acquired during day 7. In 3 horses, the device was intentionally overinflated to evaluate for device failure, and postmortem examinations were performed on day 7. For the remaining 4 horses, upper respiratory tract endoscopy was repeated at 1 month postoperatively, with no subsequent postmortem exam.
RESULTS: No perioperative complications occurred, and the DLPS was effectively delivered in all horses under standing sedation. The left-to-right quotient ratio at day 7 postoperatively could be altered from a resting position of 0.76 (± 0.06) to a maximum of 0.97 (± 0.06; P < .05). The degree of arytenoid abduction could not be significantly altered after 1 month of device implantation, suspected to be due to peri-implant fibrosis. No coughing nor tracheal contamination was observed at all time points or during inflation.
CLINICAL RELEVANCE: The ability to alter the degree of abduction at 7 days postoperatively with the DLPS may be beneficial in selective cases.
An antimicrobial skin composition comprised of an antimicrobial agent, an alcohol, one or more pH sensitive viscosity builders and water. Preferably, the viscosity builders of the present invention are comprised of pH sensitive methacrylic polymers which are alcohol compatible and have pH controlled water solubility. The composition combines the advantages of an antimicrobial agent and an alcohol, and has a viscosity of from 100 cp to 1,000. This viscosity is sufficiently low for purposes of dispensing and applying the preparation, yet sufficiently high to cause the solution to remain in the area of the wound and not flow away or pool under the patient. The preparation further forms a water-resistant film that is difficult to remove during wound irrigation, but can be easily removed upon completion of the procedure. Finally, the preparation is fast drying so as to take advantage of the fast high initial kill properties of alcohol.